<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221152</url>
  </required_header>
  <id_info>
    <org_study_id>190020</org_study_id>
    <nct_id>NCT04221152</nct_id>
  </id_info>
  <brief_title>A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )</brief_title>
  <acronym>EMPIRE-02</acronym>
  <official_title>A Multicenter, Open-label, Single-arm, Extension Study With Regard to the Safety and Efficacy of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe University</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kobe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy&#xD;
      of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety and efficacy of oral administration of empagliflozin 10 mg or 25 mg&#xD;
      once daily for 28 weeks (52 weeks of the EMPIRE-01 study) in subjects who participated in the&#xD;
      EMPIRE-01 study, which was conducted on refractory diabetes mellitus patients with insulin&#xD;
      resistance (insulin resistance syndrome, lipoatrophic diabetes mellitus) in a multicenter,&#xD;
      open-label, single-arm, extension study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, Adverse drug reactions, and Presence/absence of the use of rescue treatment drugs</measure>
    <time_frame>until Week 28 (Week 52 of the EMPIRE-01 study)</time_frame>
    <description>Presence/absence of adverse events, adverse drug reactions, and use of rescue treatment drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c change rate at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline</measure>
    <time_frame>at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline</time_frame>
    <description>The HbA1c change rate at Week 28 (52) from baseline is defined as HbA1c change from baseline divided by baseline HbA1c of the EMPIRE-01 study and multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c change at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline</measure>
    <time_frame>at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline</time_frame>
    <description>The HbA1c change at Week 28 (52) of the treatment from baseline is defined as the difference in HbA1c levels between Week 28 (52) and baseline of the EMPIRE-01 study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at each time point</measure>
    <time_frame>at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.</time_frame>
    <description>The HbA1c at each time point is defined as the HbA1c levels at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (FPG) at each time point</measure>
    <time_frame>at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.</time_frame>
    <description>The FPG at each time point is defined as the FPG levels at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (FPG) change at Week 28 (52) of the treatment from baseline</measure>
    <time_frame>between Week 28 (52) and baseline of the EMPIRE-01 study.</time_frame>
    <description>The FPG change at Week 28 (52) of the treatment from baseline is defined as the difference in the FPG levels between Week 28 (52) and baseline of the EMPIRE-01 study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose at each time point (TDD, TBD)</measure>
    <time_frame>at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.</time_frame>
    <description>The TDD and TBD at each time point are defined as the insulin doses at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose for 2 hours over time</measure>
    <time_frame>for 14 days starting from Week 12 (36)</time_frame>
    <description>Postprandial glucose for 2 hours shall be measured for 14 days starting from Week 12 (36) by using FreeStyle Librae ProTM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Insulin Resistance - Type A</condition>
  <condition>Insulin Resistance - Type B</condition>
  <condition>Lipoatrophic Diabetes Mellitus</condition>
  <condition>Insulin Resistance Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment of empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study.&#xD;
The administration is oral administration with water once daily before or after breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Tablets</intervention_name>
    <description>The administration is oral administration with water before or after breakfast.</description>
    <arm_group_label>Treatment of empagliflozin</arm_group_label>
    <other_name>BI10773</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A patient who completed the preceding EMPIRE-01 study and does not meet any&#xD;
             discontinuation criteria&#xD;
&#xD;
          2. A patient who has received sufficient explanation with regard to information such as&#xD;
             the objectives and details of this study, expected drug efficacy/pharmacological&#xD;
             action and risks, and has given written consent by her/himself&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A patient with a medical history of acute coronary syndrome (including&#xD;
             non-ST-elevation myocardial infarction, ST-elevation myocardial infarction and&#xD;
             unstable angina pectoris), stroke or transient ischemic attack (TIA) within 3 months&#xD;
             before obtaining consent&#xD;
&#xD;
          2. A patient with suspected hepatic dysfunction that either of serum ALT, AST or alkaline&#xD;
             phosphatase is exceeding 3-fold of upper limit of normal range prior to starting&#xD;
             extension study treatment (Day 0)&#xD;
&#xD;
          3. A patient who is receiving a systemic steroid at the time of consent (except for type&#xD;
             B)&#xD;
&#xD;
          4. A patient whose thyroid hormone product dose has been changed within 6 weeks before&#xD;
             obtaining consent&#xD;
&#xD;
          5. A patient with unstable endocrine diseases other than diabetes mellitus&#xD;
&#xD;
          6. A patient with hemolysis or blood diseases that destabilize erythrocytic cells and&#xD;
             other various disorders (e.g., malaria, babesiosis, hemolytic anemia)&#xD;
&#xD;
          7. A premenopausal female patient (the latest menstruation was within 1 year before&#xD;
             obtaining consent), a lactating or pregnant patient, or a patient who may be pregnant&#xD;
             (without hysterectomy or ovariectomy) who has no intention to use efficacious&#xD;
             contraception defined in this study during the study period and would not agree to&#xD;
             receive regular pregnancy tests during the study period&#xD;
&#xD;
          8. A patient who has experienced alcohol abuse or drug abuse within 3 months before&#xD;
             obtaining consent, which may disturb the study participation&#xD;
&#xD;
          9. A patient who is in the condition that makes it difficult to administer the study drug&#xD;
&#xD;
         10. A patient with renal dysfunction of eGFR (MDRD calculating formula) &lt;45 mL/min/1.73 m2&#xD;
             prior to starting extension study treatment (Day 0)&#xD;
&#xD;
         11. A patient who indicates a hypersensitivity response to empagliflozin or its&#xD;
             excipients, or a patient with lactose-intolerance&#xD;
&#xD;
         12. A patient with severe ketosis, diabetic coma or precoma, severe infection,&#xD;
             perioperative status, or serious trauma&#xD;
&#xD;
         13. A patient that the investigator and/or coinvestigator, etc., has judged to be&#xD;
             ineligible to this study for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wataru Ogawa</last_name>
    <role>Study Chair</role>
    <affiliation>Kobe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospita</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIhon University Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe University</investigator_affiliation>
    <investigator_full_name>Wataru Ogawa</investigator_full_name>
    <investigator_title>Professor, Division of Diabetes and Endocrinology</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>refractory diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus, Lipoatrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

